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C
-reactive protein (CRP) is a liver-derived protein
whose concentration increases manyfold during
inﬂammation or infection, making it a useful
diagnostic and treatment measure in diseases
such as rheumatoid arthritis. However, in the last decade,
CRP has garnered interest as a biomarker of vascular risk
that has stimulated more studies than perhaps any other
“novel” biomarker. In these studies, the much lower CRP
values seen in healthy individuals free from overt infection
or inﬂammation, detected by a new generation of sensitive
assays, have been associated in study after study with the
risk of a ﬁrst cardiovascular event (rev. in 1). Yet, despite
the consistency of this association, whether CRP is caus-
ally involved in atherogenesis or whether it helps in
prediction of cardiovascular disease (CVD) events remains
intensely controversial (2,3).
In light of this controversy, studies examining the asso-
ciation of CRP with vascular outcome and mortality in
patient populations, such as those with diabetes, where
prospective data remain relatively sparse are to be wel-
comed. In the current issue of Diabetes, Bruno et al. (4)
report that although CRP was related to risk of all-cause
and CVD mortality in their 5-year follow-up of the Casale
Monferrato Study, the improvement in individual risk
prediction beyond established risk markers, evaluated by
a range of statistical tests, was marginal at best. The
results from this helpful study, therefore, currently caution
against routine measurement of CRP for risk prediction in
diabetes patients.
Why should CRP not better predict risk in individuals,
given its consistent association with CVD and mortality?
Several issues contribute. The association of CRP with
incident events is linear when both CRP values and risk
are plotted on a log scale, with no threshold value of CRP
above which risk is substantial and below which it is
negligible. This means that individuals in a population with
intermediate values of CRP are at moderate risk of events.
Moreover, the distribution of CRP in a population is log
(normal), such that most individuals have intermediate
values of CRP. Thus, a large proportion of events would be
expected among people with nearly average CRP values,
which explains the wide overlap in the distribution of CRP
values among those who remain disease free and those
who later suffer events (whether fatal or nonfatal) (respec-
tively 2.5 mg/l [95% CI 1.2–5.3] and 3.7 mg/l [1.6–9.1] in the
study by Bruno et al. [4]). With the broad overlap, it is
difﬁcult to set CRP cut point values that adequately
discriminate later cases from those remaining disease free,
accounting for the modest C-statistic. Additionally, the
modest incremental risk prediction of CRP also stems
from the correlation of CRP with a range of established
risk factors (e.g., lipids, BMI, blood pressure, and glycemia
indexes), an observation conﬁrmed by Bruno et al. (4).
In a recent systematic review of 31 prospective cohorts
(1), CRP did not perform better than the established
Framingham risk equation for discrimination. Moreover,
improvement in risk stratiﬁcation or reclassiﬁcation from
the addition of CRP was small and inconsistent (1). As
such, the conclusion by Bruno et al. (4) regarding the
marginal value of CRP in predicting mortality risk in
diabetic patients should not be too surprising. The efforts
of the Emerging Risk Factors Collaboration (5), which has
established a central database of over 1.1 million partici-
pants from 104 prospective population-based studies, in
which subsets have information on inﬂammatory markers
as well as major cardiovascular morbidity and cause-
speciﬁc mortality, will help deﬁne whether there are
subgroups of risk in which CRP measurement will be more
helpful.
Of course, CRP is not the only “new” risk factor being
considered for a role in CVD risk prediction (6). Indeed,
measures of obesity, socioeconomic status, and family
history of premature CVD all in part capture inﬂammation
signals, and all may be more easily obtained than CRP. A
signiﬁcant correlation to inﬂammation is also evident for
the ankle-brachial index (7), a measure that appears to
signiﬁcantly enhance risk prediction beyond the Framing-
ham risk score (8).
Irrespective of its use as a risk predictor (which does
not require that CRP be causally involved in vascular
disease), there is equal interest in whether CRP is causal
and thus whether lowering it will reduce CVD risk. Estab-
lished and proven causal risk factors such as blood
pressure and cholesterol are individually poorly predictive
of incident disease (9). This is again because of the
log-linear association with risk and the normal distribution
of these risk factors in populations, which again means
that a major proportion of events occur among those with
average blood pressure or cholesterol. Thus, a risk factor
that is causally involved in atherosclerosis need not be a
good predictive tool. Although some in vitro studies have
suggested a causal role for CRP in atherogenesis, some of
the effects may have been due to the contamination of
commercial CRP preparations (10). Observational studies
are also not able to assess unequivocally whether CRP is
causally related to vascular disease because higher CRP
values in people at higher risk of disease could simply
mark other risk factors (confounding) or subclinical ath-
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798 DIABETES, VOL. 58, APRIL 2009erosclerosis (reverse causation). In the absence of a
clinical trial of a speciﬁc CRP-lowering agent, genetic
studies utilizing common variants in the CRP gene that
affect its level can be used as a type of natural randomized
trial (11). Genetic variants are allocated at random accord-
ing to Mendel’s Laws (Mendelian randomization), which
means that factors that could confound the association of
CRP itself with disease risk should distribute evenly
among the genotypic groups (12). If CRP was causally
involved in vascular disease, individuals with a high CRP
genotype should have a greater degree of atherosclerosis
and a higher risk of incident events. Such studies to date
provide no strong evidence for a causal role for CRP in
atherosclerosis or the risk of a ﬁrst vascular event (13–15).
A very-large-scale analysis using this approach is now in
progress (16). Moreover, multiple observations demon-
strating that CRP is as strongly linked to risk of non-
cardiovascular mortality (2) further argue against a causal
role for CRP in CVD but suggest that the association might,
in part, reﬂect reverse causation. Of interest, interleukin
(IL)-6 may be linked more strongly to risk for CHD events
in the general population than CRP (17), and there are
more reasons to consider IL-6 as a potentially causal
factor. However, such work is in its infancy, and no ﬁrm
conclusions on IL-6 can currently be made.
Some commentators have argued that the results of the
recent JUPITER (Justiﬁcation for the Use of Statins in
Primary Prevention: an Intervention Trial Evaluating Ro-
suvastatin) trial provide conﬁrmation of the value of CRP
in determining CVD risk (18). However, JUPITER was a
randomized controlled trial of a statin in people with low
LDL cholesterol but high CRP. Statins lower CRP but also
lower LDL cholesterol, and so it can be difﬁcult to distin-
guish whether reductions in risk observed were due to
LDL lowering, CRP lowering, or some combination. This is
the case even among people with low starting LDL cho-
lesterol concentration because of the log-linear associa-
tion of LDL cholesterol with vascular risk over the whole
range of usual values (19), which suggests that a salutary
effect of LDL cholesterol lowering might be expected
irrespective of the starting LDL cholesterol value.
In summary, therefore, although CRP commands much
interest as a CVD risk factor, higher-resolution observa-
tional epidemiology (such as that in the Emerging Risk
Factors Collaboration [5]), continued genetic epidemiol-
ogy, and eventually speciﬁc CRP inhibitors (20) are
needed to help the vascular risk community make a more
balanced judgment on any causal role and utility of CRP as
a predictor of risk. Such efforts also need to be cognizant
of a range of competing and overlapping risk factors, since
some may have distinct beneﬁts over CRP. Presently,
therefore, the current focus in clinical practice should
remain on established risk factors (e.g., smoking, lipids,
and blood pressure), both in determining coronary heart
disease risk and as targets for prevention.
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